Harriette Van Spall, MD MPH 🇨🇦

@hvanspall · @hvanspall.bsky.social · joined 16 Sep 2017

Cardiologist @McMasterU, Sr Scientist @PHRIresearch, #Implementation Dir @BaimInstitute, Editor @CircAHA, ChairElect @American_Heart #HF Council, Alum @Harvard

18 480Followers

2 082Following

45 538Posts total

10.6KViews on collected posts

Postingan terbaru

Harriette Van Spall, MD MPH 🇨🇦@hvanspall1 Sep

#Hypertension is a leading cause of #CVDs, but under-treated I enjoyed this #ESCCongress discussion w/ Prof @kazemr about his IPD on #BP⬇️ across baseline CV risk BP⬇️ -> consistent RRR across risk categories, w/ variation in safety Will it change practice? @HeartOTXHeartMD 2.1K views · 23 likes · 8 reposts · 2 replies Open on X →

Harriette Van Spall, MD MPH 🇨🇦@hvanspall30 Aug

In this stepped-wedge cluster #RCT of 19🏥s & 67K presentations of chest pain, implementation of a 0/1-hr #hsTpn pathway had non-inferior safety & similar ED LOS as 0/3-hr pathway Fun discussion on trial methods & challenges of #implementation trials #PRESC1SE-MI #ESCCongress ht 1.4K views · 15 likes · 5 reposts · 1 replies Open on X →

Harriette Van Spall, MD MPH 🇨🇦@hvanspall30 Aug

#AMUNDSEN international RCT compared strategy of #PCSK9i (#evolocumab) in cath lab + standard care vs standard care alone in 2166 patients w #ACS undergoing PCI. At 12 mo ⬆️⬆️ in LDL control ↔️ death or CV 🏥 Will it change practice? Listen to prof Monteluscat #ESCcongress h 1.3K views · 13 likes · 4 reposts · 2 replies Open on X →

Harriette Van Spall, MD MPH 🇨🇦@hvanspall29 Aug

🎙️ Dr Van Spall & Dr Jasper Boeddinghaus discuss PRESC1SE-MI from #ESCCongress2026 Implementation of the ESC 0/1-hour pathway achieved: 📊 67,624 patient presentations 📊 Earlier repeat hs-cTn testing (190 min → 86 min) ✅ Non-inferior for death or new type 1 MI 🏥 No reduction http 1.8K views · 4 likes · 1 reposts · 0 replies Open on X →

Harriette Van Spall, MD MPH 🇨🇦@hvanspall29 Aug

Can we lower risk after MI by lowering LDL-C earlier? 🎙️ At #ESCCongress2026, Dr Harriette Van Spall speaks with Prof Gilles Montalescot about #AMUNDSEN, a trial evaluating evolocumab before PCI in STEMI and NSTEMI patients. A fascinating discussion on timing, prevention and h 1.8K views · 3 likes · 1 reposts · 0 replies Open on X →

Harriette Van Spall, MD MPH 🇨🇦@hvanspall29 Aug

Oh dear! Wrong take on the data and discordant with the authors’ conclusions in the manuscript. #ESCCongress 2.2K views · 15 likes · 1 reposts · 0 replies Open on X →

Harriette Van Spall, MD MPH 🇨🇦@hvanspall26 Jul 2022

Thank you @CIHR_IRSC @SCC_CCS for this award which I don’t deserve so early in mid-career, but which I’m grateful for. Indebted to my family, team, collaborators, funders, & to 🇨🇦 for giving this immigrant a chance. So grateful to my nominators. Miss you, dad.. this one’s for you 0 views · 262 likes · 22 reposts · 19 replies Open on X →

Harriette Van Spall, MD MPH 🇨🇦@hvanspall25 Jul 2022

📢 Congratulations to Dr. Harriette Van Spall, recipient of the 2022 CIHR-ICRH/CCS Mid-Career Lecturer Award in Cardiovascular Sciences! Learn more: https://t.co/LmcKgqZq6P @SCC_CCS https://t.co/qV5Tm9Zs4r 0 views · 187 likes · 28 reposts · 52 replies Open on X →

Dibandingkan akun berukuran sama

6 postingan dari 90 hari terakhir, dibandingkan dengan rentang 10K–100K pengikut. tampil luas, tetapi sedikit penonton yang merespons.

Median tayangan1 807akun ini924median untuk 10K–100K

Jangkauan, %9.78%akun ini3.62%median untuk 10K–100K

Interaksi, %1.12%akun ini1.52%median untuk 10K–100K

Metrik	Akun ini	Median untuk 10K–100K	Rasio
Median tayangan per postingan	1 807	924	1.96×
Jangkauan (tayangan ÷ pengikut)	9.78%	3.62%	2.70×
Tingkat interaksi	1.12%	1.52%	0.74×

Akun lain pada rentang ini → Bandingkan dengan akun lain → Bagaimana tolok ukur ini disusun →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.